Urij Rampampam

Research Profile

Chemicals & Drugs

Living Beings

Concepts & Ideas

Anatomy

Brain

Disorders

Animal Disease Models

Co-author Network

Publications

TOP 3
E M Rock; D Bolognini; C L Limebeer; M G Cascio; S Anavi-Goffer; P J Fletcher; R Mechoulam; R G Pertwee; L A Parker
Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus.
Erin M Rock; Jennifer M Goodwin; Cheryl L Limebeer; Aviva Breuer; Roger G Pertwee; Raphael Mechoulam; Linda A Parker
Interaction between non-psychotropic cannabinoids in marihuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews.
Athanasios Lourbopoulos; Nikolaos Grigoriadis; Roza Lagoudaki; Olga Touloumi; Eleni Polyzoidou; Ioannis Mavromatis; Nikolaos Tascos; Aviva Breuer; Haim Ovadia; Dimitris Karussis; et al.
Administration of 2-arachidonoylglycerol ameliorates both acute and chronic experimental autoimmune encephalomyelitis.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Urij Rampampam (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: E M Rock; D Bolognini; C L Limebeer; M G Cascio; S Anavi-Goffer; P J Fletcher; R Mechoulam; R G Pertwee; L A Parker
Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus.
British journal of pharmacology 2012;165(8):2620-34.
2011: Erin M Rock; Jennifer M Goodwin; Cheryl L Limebeer; Aviva Breuer; Roger G Pertwee; Raphael Mechoulam; Linda A Parker
Interaction between non-psychotropic cannabinoids in marihuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews.
Psychopharmacology 2011;215(3):505-12.
2011: Athanasios Lourbopoulos; Nikolaos Grigoriadis; Roza Lagoudaki; Olga Touloumi; Eleni Polyzoidou; Ioannis Mavromatis; Nikolaos Tascos; Aviva Breuer; Haim Ovadia; Dimitris Karussis; et al.
Administration of 2-arachidonoylglycerol ameliorates both acute and chronic experimental autoimmune encephalomyelitis.
Brain research 2011;1390():126-41.
2011: Y Avraham; Nc Grigoriadis; T Poutahidis; L Vorobiev; I Magen; Y Ilan; R Mechoulam; Em Berry
Cannabidiol improves brain and liver function in a fulminant hepatic failure-induced model of hepatic encephalopathy in mice.
British journal of pharmacology 2011;162(7):1650-8.
2010: R G Pertwee; A C Howlett; M E Abood; S P H Alexander; V Di Marzo; M R Elphick; P J Greasley; H S Hansen; G Kunos; K Mackie; et al.
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.
Pharmacological reviews 2010;62(4):588-631.
2010: Reem Smoum; Arik Bar; Bo Tan; Garry Milman; Malka Attar-Namdar; Orr Ofek; Jordyn M Stuart; Alon Bajayo; Joseph Tam; Vardit Kram; et al.
Oleoyl serine, an endogenous N-acyl amide, modulates bone remodeling and mass.
Proceedings of the National Academy of Sciences of the United States of America 2010;107(41):17710-5.
2010: Iain Brown; Maria G Cascio; Klaus W J Wahle; Reem Smoum; Raphael Mechoulam; Ruth A Ross; Roger G Pertwee; Steven D Heys
Cannabinoid receptor-dependent and -independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor-positive and -negative prostate cancer cell lines.
Carcinogenesis 2010;31(9):1584-91.
2010: Raphael Mechoulam
[Endocannabinoids and psychiatric disorders: the road ahead].
Revista brasileira de psiquiatria (São Paulo, Brazil : 1999) 2010;32 Suppl 1():S5-6.
2010: I Magen; Y Avraham; Z Ackerman; L Vorobiev; R Mechoulam; E M Berry
Cannabidiol ameliorates cognitive and motor impairments in bile-duct ligated mice via 5-HT1A receptor activation.
British journal of pharmacology 2010;159(4):950-7.
2010: Lumír O Hanus; Raphael Mechoulam
Novel natural and synthetic ligands of the endocannabinoid system.
Current medicinal chemistry 2010;17(14):1341-59.
2009: Arieh Moussaieff; Raphael Mechoulam
Boswellia resin: from religious ceremonies to medical uses; a review of in-vitro, in-vivo and clinical trials.
The Journal of pharmacy and pharmacology 2009;61(10):1281-93.
2009: Y Avraham; N C Grigoriadis; I Magen; T Poutahidis; L Vorobiav; O Zolotarev; Y Ilan; R Mechoulam; E M Berry
Capsaicin affects brain function in a model of hepatic encephalopathy associated with fulminant hepatic failure in mice.
British journal of pharmacology 2009;158(3):896-906.
2009: Angelo A Izzo; Francesca Borrelli; Raffaele Capasso; Vincenzo Di Marzo; Raphael Mechoulam
Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb.
Trends in pharmacological sciences 2009;30(10):515-27.
2009: Iddo Magen; Yosefa Avraham; Zvi Ackerman; Lia Vorobiev; Raphael Mechoulam; Elliot M Berry
Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation.
Journal of hepatology 2009;51(3):528-34.
2009: Onintza Sagredo; Sara González; Ilia Aroyo; María Ruth Pazos; Cristina Benito; Isabel Lastres-Becker; Juan P Romero; Rosa M Tolón; Raphael Mechoulam; Emmanuel Brouillet; et al.
Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease.
Glia 2009;57(11):1154-67.
2008: Eric Murillo-Rodríguez; Diana Millán-Aldaco; Marcela Palomero-Rivero; Raphael Mechoulam; René Drucker-Colín
The nonpsychoactive Cannabis constituent cannabidiol is a wake-inducing agent.
Behavioral neuroscience 2008;122(6):1378-82.
2008: Deborah Patinkin; Garry Milman; Aviva Breuer; Ester Fride; Raphael Mechoulam
Endocannabinoids as positive or negative factors in hematopoietic cell migration and differentiation.
European journal of pharmacology 2008;595(1-3):1-6.
2008: Arieh Moussaieff; Neta Rimmerman; Tatiana Bregman; Alex Straiker; Christian C Felder; Shai Shoham; Yoel Kashman; Susan M Huang; Hyosang Lee; Esther Shohami; et al.
Incensole acetate, an incense component, elicits psychoactivity by activating TRPV3 channels in the brain.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2008;22(8):3024-34.
2008: Arieh Moussaieff; Na'ama A Shein; Jeanna Tsenter; Savvas Grigoriadis; Constantina Simeonidou; Alexander G Alexandrovich; Victoria Trembovler; Yinon Ben-Neriah; Michael L Schmitz; Bernd L Fiebich; et al.
Incensole acetate: a novel neuroprotective agent isolated from Boswellia carterii.
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 2008;28(7):1341-52.
2008: A Weinstein; O Brickner; H Lerman; M Greemland; M Bloch; H Lester; R Chisin; Y Sarne; R Mechoulam; R Bar-Hamburger; et al.
A study investigating the acute dose-response effects of 13 mg and 17 mg Delta 9- tetrahydrocannabinol on cognitive-motor skills, subjective and autonomic measures in regular users of marijuana.
Journal of psychopharmacology (Oxford, England) 2008;22(4):441-51.
2008: Javier Palazuelos; Nathalie Davoust; Boris Julien; Eric Hatterer; Tania Aguado; Raphael Mechoulam; Cristina Benito; Julian Romero; Augusto Silva; Manuel Guzmán; et al.
The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis.
The Journal of biological chemistry 2008;283(19):13320-9.
2008: Adi Ronen; Pnina Gershon; Hanan Drobiner; Alex Rabinovich; Rachel Bar-Hamburger; Raphael Mechoulam; Yair Cassuto; David Shinar
Effects of THC on driving performance, physiological state and subjective feelings relative to alcohol.
Accident; analysis and prevention 2008;40(3):926-34.
2008: Erin M Rock; Cheryl L Limebeer; Raphael Mechoulam; Daniele Piomelli; Linda A Parker
The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat.
Psychopharmacology 2008;196(3):389-95.
2008: Douglas McHugh; Carolyn Tanner; Raphael Mechoulam; Roger G Pertwee; Ruth A Ross
Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2.
Molecular pharmacology 2008;73(2):441-50.
2008: Iddo Magen; Yosefa Avraham; Elliot Berry; Raphael Mechoulam
Endocannabinoids in liver disease and hepatic encephalopathy.
Current pharmaceutical design 2008;14(23):2362-9.
2008: Gil Galanti; Tamar Fisher; Iris Kventsel; Jacob Shoham; Ruth Gallily; Raphael Mechoulam; Gad Lavie; Ninette Amariglio; Gideon Rechavi; Amos Toren
Delta 9-tetrahydrocannabinol inhibits cell cycle progression by downregulation of E2F1 in human glioblastoma multiforme cells.
Acta oncologica (Stockholm, Sweden) 2008;47(6):1062-70.
2008: Aviv Weinstein; Orit Brickner; Hedva Lerman; Mazal Greemland; Miki Bloch; Hava Lester; Roland Chisin; Raphael Mechoulam; Rachel Bar-Hamburger; Nanette Freedman; et al.
Brain imaging study of the acute effects of Delta9-tetrahydrocannabinol (THC) on attention and motor coordination in regular users of marijuana.
Psychopharmacology 2008;196(1):119-31.
2008: Lola Weiss; Michael Zeira; Shoshana Reich; Shimon Slavin; Itamar Raz; Raphael Mechoulam; Ruth Gallily
Cannabidiol arrests onset of autoimmune diabetes in NOD mice.
Neuropharmacology 2008;54(1):244-9.
2008: Joseph Tam; Victoria Trembovler; Vincenzo Di Marzo; Stefania Petrosino; Gabriella Leo; Alex Alexandrovich; Eran Regev; Nardy Casap; Arie Shteyer; Catherine Ledent; et al.
The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2008;22(1):285-94.
2007: Arieh Moussaieff; Esther Shohami; Yoel Kashman; Ester Fride; M Lienhard Schmitz; Florian Renner; Bernd L Fiebich; Eduardo Munoz; Yinon Ben-Neriah; Raphael Mechoulam
Incensole acetate, a novel anti-inflammatory compound isolated from Boswellia resin, inhibits nuclear factor-kappa B activation.
Molecular pharmacology 2007;72(6):1657-64.
2007: Ronen Durst; Haim Danenberg; Ruth Gallily; Raphael Mechoulam; Keren Meir; Etty Grad; Ronen Beeri; Thea Pugatsch; Elizabet Tarsish; Chaim Lotan
Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury.
American journal of physiology. Heart and circulatory physiology 2007;293(6):H3602-7.
2007: R Mechoulam; E Shohami
Endocannabinoids and traumatic brain injury.
Molecular neurobiology 2007;36(1):68-74.
2007: Raphael Mechoulam; Maximilian Peters; Eric Murillo-Rodriguez; Lumír O Hanus
Cannabidiol--recent advances.
Chemistry & biodiversity 2007;4(8):1678-92.
2007: Onintza Sagredo; José A Ramos; Alessandra Decio; Raphael Mechoulam; Javier Fernández-Ruiz
Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors.
The European journal of neuroscience 2007;26(4):843-51.
2007: Yossi Dagon; Yosefa Avraham; Gabriela Link; Olga Zolotarev; Raphael Mechoulam; Elliot M Berry
The synthetic cannabinoid HU-210 attenuates neural damage in diabetic mice and hyperglycemic pheochromocytoma PC12 cells.
Neurobiology of disease 2007;27(2):174-81.
2007: Natalya M Kogan; Michael Schlesinger; Maximilian Peters; Gergana Marincheva; Ronen Beeri; Raphael Mechoulam
A cannabinoid anticancer quinone, HU-331, is more potent and less cardiotoxic than doxorubicin: a comparative in vivo study.
The Journal of pharmacology and experimental therapeutics 2007;322(2):646-53.
2007: Yossi Dagon; Yosefa Avraham; Yaron Ilan; Raphael Mechoulam; Elliot M Berry
Cannabinoids ameliorate cerebral dysfunction following liver failure via AMP-activated protein kinase.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2007;21(10):2431-41.
2007: Meliha Karsak; Evelyn Gaffal; Rahul Date; Lihua Wang-Eckhardt; Jennifer Rehnelt; Stefania Petrosino; Katarzyna Starowicz; Regina Steuder; Eberhard Schlicker; Benjamin Cravatt; et al.
Attenuation of allergic contact dermatitis through the endocannabinoid system.
Science (New York, N.Y.) 2007;316(5830):1494-7.
2007: Raphael Mechoulam
Conversation with Raphael Mechoulam.
Addiction (Abingdon, England) 2007;102(6):887-93.
2007: Tania Aguado; Arkaitz Carracedo; Boris Julien; Guillermo Velasco; Garry Milman; Raphael Mechoulam; Luis Alvarez; Manuel Guzmán; Ismael Galve-Roperh
Cannabinoids induce glioma stem-like cell differentiation and inhibit gliomagenesis.
The Journal of biological chemistry 2007;282(9):6854-62.
2007: Moisés García-Arencibia; Sara González; Eva de Lago; José A Ramos; Raphael Mechoulam; Javier Fernández-Ruiz
Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties.
Brain research 2007;1134(1):162-70.
2007: Natalya M Kogan; Raphael Mechoulam
Cannabinoids in health and disease.
Dialogues in clinical neuroscience 2007;9(4):413-30.
2007: Natalya M Kogan; Michael Schlesinger; Esther Priel; Ruth Rabinowitz; Eduard Berenshtein; Mordechai Chevion; Raphael Mechoulam
HU-331, a novel cannabinoid-based anticancer topoisomerase II inhibitor.
Molecular cancer therapeutics 2007;6(1):173-83.
2006: Javier Palazuelos; Tania Aguado; Ainara Egia; Raphael Mechoulam; Manuel Guzmán; Ismael Galve-Roperh
Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2006;20(13):2405-7.
2006: Joseph Tam; Orr Ofek; Ester Fride; Catherine Ledent; Yankel Gabet; Ralph Müller; Andreas Zimmer; Ken Mackie; Raphael Mechoulam; Esther Shohami; et al.
Involvement of neuronal cannabinoid receptor CB1 in regulation of bone mass and bone remodeling.
Molecular pharmacology 2006;70(3):786-92.
2006: Eric Murillo-Rodríguez; Diana Millán-Aldaco; Marcela Palomero-Rivero; Raphael Mechoulam; René Drucker-Colín
Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats.
FEBS letters 2006;580(18):4337-45.
2006: Natalya M Kogan; Cristina Blázquez; Luis Alvarez; Ruth Gallily; Michael Schlesinger; Manuel Guzmán; Raphael Mechoulam
A cannabinoid quinone inhibits angiogenesis by targeting vascular endothelial cells.
Molecular pharmacology 2006;70(1):51-9.
2006: David Panikashvili; Na'ama A Shein; Raphael Mechoulam; Victoria Trembovler; Ron Kohen; Alexander Alexandrovich; Esther Shohami
The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines.
Neurobiology of disease 2006;22(2):257-64.
2006: Esther Shohami; Raphael Mechoulam
Multiple sclerosis may disrupt endocannabinoid brain protection mechanism.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(16):6087-8.
2006: R Mechoulam; E M Berry; Y Avraham; V Di Marzo; E Fride
Endocannabinoids, feeding and suckling--from our perspective.
International journal of obesity (2005) 2006;30 Suppl 1():S24-8.
2006: L Weiss; M Zeira; S Reich; M Har-Noy; R Mechoulam; S Slavin; R Gallily
Cannabidiol lowers incidence of diabetes in non-obese diabetic mice.
Autoimmunity 2006;39(2):143-51.
2006: Garry Milman; Yehoshua Maor; Saleh Abu-Lafi; Michal Horowitz; Ruth Gallily; Sandor Batkai; Fong-Ming Mo; Laszlo Offertaler; Pal Pacher; George Kunos; et al.
N-arachidonoyl L-serine, an endocannabinoid-like brain constituent with vasodilatory properties.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(7):2428-33.
2006: Linda A Parker; Magdalena Kwiatkowska; Raphael Mechoulam
Delta-9-tetrahydrocannabinol and cannabidiol, but not ondansetron, interfere with conditioned retching reactions elicited by a lithium-paired context in Suncus murinus: An animal model of anticipatory nausea and vomiting.
Physiology & behavior 2006;87(1):66-71.
2006: Orr Ofek; Meliha Karsak; Nathalie Leclerc; Meirav Fogel; Baruch Frenkel; Karen Wright; Joseph Tam; Malka Attar-Namdar; Vardit Kram; Esther Shohami; et al.
Peripheral cannabinoid receptor, CB2, regulates bone mass.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(3):696-701.
2006: N M Kogan; R Mechoulam
The chemistry of endocannabinoids.
Journal of endocrinological investigation 2006;29(3 Suppl):3-14.
2006: Yosefa Avraham; Eran Israeli; Ezra Gabbay; Avital Okun; Olga Zolotarev; Isable Silberman; Vera Ganzburg; Yossi Dagon; Iddo Magen; Lia Vorobia; et al.
Endocannabinoids affect neurological and cognitive function in thioacetamide-induced hepatic encephalopathy in mice.
Neurobiology of disease 2006;21(1):237-45.
2005: Raphael Mechoulam; Dale G Deutsch
Toward an anandamide transporter.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(49):17541-2.
2005: Yosef Sarne; Raphael Mechoulam
Cannabinoids: between neuroprotection and neurotoxicity.
Current drug targets. CNS and neurological disorders 2005;4(6):677-84.
2005: Raphael Mechoulam
Plant cannabinoids: a neglected pharmacological treasure trove.
British journal of pharmacology 2005;146(7):913-5.
2005: A Moussaieff; E Fride; Z Amar; E Lev; D Steinberg; R Gallily; R Mechoulam
The Jerusalem Balsam: from the Franciscan Monastery in the old city of Jerusalem to Martindale 33.
Journal of ethnopharmacology 2005;101(1-3):16-26.
2005: Christian Unzicker; Heike Erberich; Gabriella Moldrich; Helge Woldt; Jan Bulla; Raphael Mechoulam; Hannelore Ehrenreich; Anna-Leena Sirén
Hippocampal cannabinoid-1 receptor upregulation upon endothelin-B receptor deficiency: a neuroprotective substitution effect?
Neurochemical research 2005;30(10):1305-9.
2005: E Fride; R Suris; J Weidenfeld; R Mechoulam
Differential response to acute and repeated stress in cannabinoid CB1 receptor knockout newborn and adult mice.
Behavioural pharmacology 2005;16(5-6):431-40.
2005: Roger G Pertwee; Adèle Thomas; Lesley A Stevenson; Yehoshua Maor; Raphael Mechoulam
Evidence that (-)-7-hydroxy-4'-dimethylheptyl-cannabidiol activates a non-CB(1), non-CB(2), non-TRPV1 target in the mouse vas deferens.
Neuropharmacology 2005;48(8):1139-46.
2005: Alexandros Makriyannis; Raphael Mechoulam; Daniele Piomelli
Therapeutic opportunities through modulation of the endocannabinoid system.
Neuropharmacology 2005;48(8):1068-71.
2005: Isabel Lastres-Becker; Francisco Molina-Holgado; José A Ramos; Raphael Mechoulam; Javier Fernández-Ruiz
Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease.
Neurobiology of disease 2005;19(1-2):96-107.
2005: David Panikashvili; Raphael Mechoulam; Sara M Beni; Alexander Alexandrovich; Esther Shohami
CB1 cannabinoid receptors are involved in neuroprotection via NF-kappa B inhibition.
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 2005;25(4):477-84.
2005: Lumír O Hanus; Susanna Tchilibon; Datta E Ponde; Aviva Breuer; Ester Fride; Raphael Mechoulam
Enantiomeric cannabidiol derivatives: synthesis and binding to cannabinoid receptors.
Organic & biomolecular chemistry 2005;3(6):1116-23.
2005: Yosefa Avraham; Avshalom Ben Menachem; Avital Okun; Olga Zlotarav; Nadav Abel; Raphael Mechoulam; Elliot M Berry
Effects of the endocannabinoid noladin ether on body weight, food consumption, locomotor activity, and cognitive index in mice.
Brain research bulletin 2005;65(2):117-23.
2004: Ester Fride; Cfir Feigin; Datta E Ponde; Aviva Breuer; Lumír Hanus; Nina Arshavsky; Raphael Mechoulam
(+)-Cannabidiol analogues which bind cannabinoid receptors but exert peripheral activity only.
European journal of pharmacology 2004;506(2):179-88.
2004: Susanne Andrea Golech; Richard M McCarron; Ye Chen; Joliet Bembry; Frederick Lenz; Raphael Mechoulam; Esther Shohami; Maria Spatz
Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors.
Brain research. Molecular brain research 2004;132(1):87-92.
2004: Linda A Parker; Page Burton; Robert E Sorge; Christine Yakiwchuk; Raphael Mechoulam
Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats.
Psychopharmacology 2004;175(3):360-6.
2004: Natalya M Kogan; Ruth Rabinowitz; Paloma Levi; Dan Gibson; Peter Sandor; Michael Schlesinger; Raphael Mechoulam
Synthesis and antitumor activity of quinonoid derivatives of cannabinoids.
Journal of medicinal chemistry 2004;47(15):3800-6.
2004: Magdalena Kwiatkowska; Linda A Parker; Page Burton; Raphael Mechoulam
A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew).
Psychopharmacology 2004;174(2):254-9.
2004: Percy F Sumariwalla; Ruth Gallily; Susanna Tchilibon; Ester Fride; Raphael Mechoulam; Marc Feldmann
A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis.
Arthritis and rheumatism 2004;50(3):985-98.
2004: Raphael Mechoulam
The promise of advances in the field of endocannabinoids.
Neuro endocrinology letters 2004;25(1-2):11-2.
2004: Roya Navab; Helena Aingorn; Lucia Fallavollita; Sara Sallon; Raphael Mechoulam; Isaac Ginsburg; Israel Vlodavsky; Pnina Brodt
PADMA-28, a traditional Tibetan herbal preparation, blocks cellular responses to bFGF and IGF-I.
Inflammopharmacology 2004;12(4):373-89.
2004: Linda A Parker; Magdalena Kwiatkowska; Page Burton; Raphael Mechoulam
Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew).
Psychopharmacology 2004;171(2):156-61.
2003: M Lodzki; B Godin; L Rakou; R Mechoulam; R Gallily; E Touitou
Cannabidiol-transdermal delivery and anti-inflammatory effect in a murine model.
Journal of controlled release : official journal of the Controlled Release Society 2003;93(3):377-87.
2003: R Mechoulam; A H Lichtman
Neuroscience. Stout guards of the central nervous system.
Science (New York, N.Y.) 2003;302(5642):65-7.
2003: Ruth Gallily; Tal Even-Chena; Galia Katzavian; Dan Lehmann; Arie Dagan; Raphael Mechoulam
Gamma-irradiation enhances apoptosis induced by cannabidiol, a non-psychotropic cannabinoid, in cultured HL-60 myeloblastic leukemia cells.
Leukemia & lymphoma 2003;44(10):1767-73.
2003: Lumír Hanus; Yosefa Avraham; Dikla Ben-Shushan; Olga Zolotarev; Elliot M Berry; Raphael Mechoulam
Short-term fasting and prolonged semistarvation have opposite effects on 2-AG levels in mouse brain.
Brain research 2003;983(1-2):144-51.
2003: Yossi Gilgun-Sherki; Eldad Melamed; Raphael Mechoulam; Daniel Offen
The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6-hydroxydopamine-lesioned rats.
Pharmacology & toxicology 2003;93(2):66-70.
2003: Ronen R Leker; Naomi Gai; Raphael Mechoulam; Haim Ovadia
Drug-induced hypothermia reduces ischemic damage: effects of the cannabinoid HU-210.
Stroke; a journal of cerebral circulation 2003;34(8):2000-6.
2003: Raphael Mechoulam; Linda Parker
Cannabis and alcohol--a close friendship.
Trends in pharmacological sciences 2003;24(6):266-8.
2003: Linda A Parker; Raphael Mechoulam
Cannabinoid agonists and antagonists modulate lithium-induced conditioned gaping in rats.
Integrative physiological and behavioral science : the official journal of the Pavlovian Society 2003;38(2):133-45.
2003: Linda A Parker; Raphael Mechoulam; Coralynn Schlievert; Laura Abbott; Melissa L Fudge; Page Burton
Effects of cannabinoids on lithium-induced conditioned rejection reactions in a rat model of nausea.
Psychopharmacology 2003;166(2):156-62.
2003: Ester Fride; Anat Foox; Elana Rosenberg; Moran Faigenboim; Vickey Cohen; Lena Barda; Hannah Blau; Raphael Mechoulam
Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: evidence for a "CB3" receptor.
European journal of pharmacology 2003;461(1):27-34.
2003: R M McCarron; E Shohami; D Panikashvili; Y Chen; S Golech; A Strasser; R Mechoulam; M Spatz
Antioxidant properties of the vasoactive endocannabinoid, 2-arachidonoyl glycerol (2-AG).
Acta neurochirurgica. Supplement 2003;86():271-5.
2002: Raphael Mechoulam; Lumír Hanus
Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects.
Chemistry and physics of lipids 2002;121(1-2):35-43.
2002: Raphael Mechoulam; Linda A Parker; Ruth Gallily
Cannabidiol: an overview of some pharmacological aspects.
Journal of clinical pharmacology 2002;42(11 Suppl):11S-19S.
2002: Krista Laine; Kristiina Järvinen; Raphael Mechoulam; Aviva Breuer; Tomi Järvinen
Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid.
Investigative ophthalmology & visual science 2002;43(10):3216-22.
2002: Elliot M Berry; Raphael Mechoulam
Tetrahydrocannabinol and endocannabinoids in feeding and appetite.
Pharmacology & therapeutics 2002;95(2):185-90.
2002: A C Howlett; F Barth; T I Bonner; G Cabral; P Casellas; W A Devane; C C Felder; M Herkenham; K Mackie; B R Martin; et al.
International Union of Pharmacology. XXVII. Classification of cannabinoid receptors.
Pharmacological reviews 2002;54(2):161-202.
2002: R Mechoulam; M Spatz; E Shohami
Endocannabinoids and neuroprotection.
Science's STKE : signal transduction knowledge environment 2002;2002(129):re5.
2002: Linda A Parker; Raphael Mechoulam; Coralynne Schlievert
Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats.
Neuroreport 2002;13(5):567-70.
2002: Filomena Fezza; Tiziana Bisogno; Alberto Minassi; Giovanni Appendino; Raphael Mechoulam; Vincenzo Di Marzo
Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for its quantification in rat tissues.
FEBS letters 2002;513(2-3):294-8.
2002: R Mechoulam
Discovery of endocannabinoids and some random thoughts on their possible roles in neuroprotection and aggression.
Prostaglandins, leukotrienes, and essential fatty acids 2002;66(2-3):93-9.
2002: Raphael Mechoulam; David Panikashvili; Esther Shohami
Cannabinoids and brain injury: therapeutic implications.
Trends in molecular medicine 2002;8(2):58-61.
2001: D Panikashvili; C Simeonidou; S Ben-Shabat; L Hanus; A Breuer; R Mechoulam; E Shohami
An endogenous cannabinoid (2-AG) is neuroprotective after brain injury.
Nature 2001;413(6855):527-31.
2001: T Bisogno; L Hanus; L De Petrocellis; S Tchilibon; D E Ponde; I Brandi; A S Moriello; J B Davis; R Mechoulam; V Di Marzo
Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide.
British journal of pharmacology 2001;134(4):845-52.
2001: E Fride; Y Ginzburg; A Breuer; T Bisogno; V Di Marzo; R Mechoulam
Critical role of the endogenous cannabinoid system in mouse pup suckling and growth.
European journal of pharmacology 2001;419(2-3):207-14.
2001: L Hanus; S Abu-Lafi; E Fride; A Breuer; Z Vogel; D E Shalev; I Kustanovich; R Mechoulam
2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor.
Proceedings of the National Academy of Sciences of the United States of America 2001;98(7):3662-5.
2000: R Mechoulam; L Hanus
A historical overview of chemical research on cannabinoids.
Chemistry and physics of lipids 2000;108(1-2):1-13.
2000: S Tchilibon; R Mechoulam
Synthesis of a primary metabolite of cannabidiol.
Organic letters 2000;2(21):3301-3.
2000: R Gallily; A Breuer; R Mechoulam
2-Arachidonylglycerol, an endogenous cannabinoid, inhibits tumor necrosis factor-alpha production in murine macrophages, and in mice.
European journal of pharmacology 2000;406(1):R5-7.
2000: Y Chen; R M McCarron; Y Ohara; J Bembry; N Azzam; F A Lenz; E Shohami; R Mechoulam; M Spatz
Human brain capillary endothelium: 2-arachidonoglycerol (endocannabinoid) interacts with endothelin-1.
Circulation research 2000;87(4):323-7.
2000: A M Malfait; R Gallily; P F Sumariwalla; A S Malik; E Andreakos; R Mechoulam; M Feldmann
The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(17):9561-6.
2000: S Hao; Y Avraham; R Mechoulam; E M Berry
Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice.
European journal of pharmacology 2000;392(3):147-56.
1999: L Hanus; A Breuer; S Tchilibon; S Shiloah; D Goldenberg; M Horowitz; R G Pertwee; R A Ross; R Mechoulam; E Fride
HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(25):14228-33.
1999: R Mechoulam
Recent advantages in cannabinoid research.
Forschende Komplementärmedizin 1999;6 Suppl 3():16-20.
1999: R Mechoulam; S Ben-Shabat
From gan-zi-gun-nu to anandamide and 2-arachidonoylglycerol: the ongoing story of cannabis.
Natural product reports 1999;16(2):131-43.
1999: I Ginsburg; M Sadovnik; S Sallon; I Milo-Goldzweig; R Mechoulam; A Breuer; D Gibbs; J Varani; S Roberts; E Cleator; et al.
PADMA-28, a traditional tibetan herbal preparation inhibits the respiratory burst in human neutrophils, the killing of epithelial cells by mixtures of oxidants and pro-inflammatory agonists and peroxidation of lipids.
Inflammopharmacology 1999;7(1):47-62.
1998: V Di Marzo; N Sepe; L De Petrocellis; A Berger; G Crozier; E Fride; R Mechoulam
Trick or treat from food endocannabinoids?
Nature 1998;396(6712):636-7.
1998: R Mechoulam; E Fride; S Ben-Shabat; U Meiri; M Horowitz
Carbachol, an acetylcholine receptor agonist, enhances production in rat aorta of 2-arachidonoyl glycerol, a hypotensive endocannabinoid.
European journal of pharmacology 1998;362(1):R1-3.
1998: R Mechoulam; E Fride; V Di Marzo
Endocannabinoids.
European journal of pharmacology 1998;359(1):1-18.
1998: S Ben-Shabat; E Fride; T Sheskin; T Tamiri; M H Rhee; Z Vogel; T Bisogno; L De Petrocellis; V Di Marzo; R Mechoulam
An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity.
European journal of pharmacology 1998;353(1):23-31.
1998: E Sulcova; R Mechoulam; E Fride
Biphasic effects of anandamide.
Pharmacology, biochemistry, and behavior 1998;59(2):347-52.
1998: R Mechoulam; L Hanus; E Fride
Towards cannabinoid drugs--revisited.
Progress in medicinal chemistry 1998;35():199-243.
1997: R Gallily; A Yamin; Y Waksmann; H Ovadia; J Weidenfeld; A Bar-Joseph; A Biegon; R Mechoulam; E Shohami
Protection against septic shock and suppression of tumor necrosis factor alpha and nitric oxide production by dexanabinol (HU-211), a nonpsychotropic cannabinoid.
The Journal of pharmacology and experimental therapeutics 1997;283(2):918-24.
1997: M H Rhee; Z Vogel; J Barg; M Bayewitch; R Levy; L Hanus; A Breuer; R Mechoulam
Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase.
Journal of medicinal chemistry 1997;40(20):3228-33.
1997: R Mechoulam; E Fride; L Hanus; T Sheskin; T Bisogno; V Di Marzo; M Bayewitch; Z Vogel
Anandamide may mediate sleep induction.
Nature 1997;389(6646):25-6.
1997: T Sheskin; L Hanus; J Slager; Z Vogel; R Mechoulam
Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor.
Journal of medicinal chemistry 1997;40(5):659-67.
1997: E Shohami; R Gallily; R Mechoulam; R Bass; T Ben-Hur
Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant.
Journal of neuroimmunology 1997;72(2):169-77.
1996: R Mechoulam; S Ben Shabat; L Hanus; E Fride; Z Vogel; M Bayewitch; A E Sulcova
Endogenous cannabinoid ligands--chemical and biological studies.
Journal of lipid mediators and cell signalling 1996;14(1-3):45-9.
1996: E Fride; R Mechoulam
Ontogenetic development of the response to anandamide and delta 9-tetrahydrocannabinol in mice.
Brain research. Developmental brain research 1996;95(1):131-4.
1996: M Bayewitch; M H Rhee; T Avidor-Reiss; A Breuer; R Mechoulam; Z Vogel
(-)-Delta9-tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase.
The Journal of biological chemistry 1996;271(17):9902-5.
1996: E Pop; F Soti; M E Brewster; Y Barenholz; V Korablyov; R Mechoulam; V Nadler; A Biegon
Derivatives of dexanabinol. II. Salts of amino acid esters containing tertiary and quaternary heterocyclic nitrogen with increased water-solubility.
Pharmaceutical research 1996;13(3):469-75.
1996: E Fride; R Mechoulam
Developmental aspects of anandamide: ontogeny of response and prenatal exposure.
Psychoneuroendocrinology 1996;21(2):157-72.
1996: R Mechoulam; S B Shabat; L Hanus; E Fride; M Bayewitch; Z Vogel
Endogenous cannabinoid ligands.
Advances in experimental medicine and biology 1996;402():95-101.
1996: E Pop; Z Z Liu; M E Brewster; Y Barenholz; V Korablyov; R Mechoulam; V Nadler; A Biegon
Derivatives of Dexanabinol. I. Water-soluble salts of glycinate esters.
Pharmaceutical research 1996;13(1):62-9.
1995: J Barg; E Fride; L Hanus; R Levy; N Matus-Leibovitch; E Heldman; M Bayewitch; R Mechoulam; Z Vogel
Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides.
European journal of pharmacology 1995;287(2):145-52.
1995: M Bayewitch; T Avidor-Reiss; R Levy; J Barg; R Mechoulam; Z Vogel
The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling.
FEBS letters 1995;375(1-2):143-7.
1995: R Mechoulam; S Ben-Shabat; L Hanus; M Ligumsky; N E Kaminski; A R Schatz; A Gopher; S Almog; B R Martin; D R Compton
Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors.
Biochemical pharmacology 1995;50(1):83-90.
1995: E Fride; J Barg; R Levy; D Saya; E Heldman; R Mechoulam; Z Vogel
Low doses of anandamides inhibit pharmacological effects of delta 9-tetrahydrocannabinol.
The Journal of pharmacology and experimental therapeutics 1995;272(2):699-707.
1994: R Mechoulam; L Hanus; B R Martin
Search for endogenous ligands of the cannabinoid receptor.
Biochemical pharmacology 1994;48(8):1537-44.
1994: R Pertwee; G Griffin; L Hanus; R Mechoulam
Effects of two endogenous fatty acid ethanolamides on mouse vasa deferentia.
European journal of pharmacology 1994;259(2):115-20.
1994: S Abu-Lafi; M Sterin; S Levin; R Mechoulam
Structural features affecting chiral discrimination of terpene derivatives on a carbamated amylose stationary phase.
Journal of chromatography. A 1994;664(2):159-67.
1994: T U Järbe; R Mechoulam; J Zahalka
Discriminative stimulus- and open-field effects of the enantiomers of 11-hydroxy-delta-8-tetrahydrocannabinol in pigeons and gerbils.
Pharmacology, biochemistry, and behavior 1994;47(1):113-9.
1993: S Levin; S Abu-Lafi; J Zahalka; R Mechoulam
Resolution of chiral cannabinoids on amylose tris(3,5-dimethylphenylcarbamate) chiral stationary phase: effects of structural features and mobile phase additives.
Journal of chromatography. A 1993;654(1):53-64.
1993: V Nadler; R Mechoulam; M Sokolovsky
The non-psychotropic cannabinoid (+)-(3S,4S)-7-hydroxy-delta 6- tetrahydrocannabinol 1,1-dimethylheptyl (HU-211) attenuates N-methyl-D-aspartate receptor-mediated neurotoxicity in primary cultures of rat forebrain.
Neuroscience letters 1993;162(1-2):43-5.
1993: L Hanus; A Gopher; S Almog; R Mechoulam
Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor.
Journal of medicinal chemistry 1993;36(20):3032-4.
1993: V Nadler; R Mechoulam; M Sokolovsky
Blockade of 45Ca2+ influx through the N-methyl-D-aspartate receptor ion channel by the non-psychoactive cannabinoid HU-211.
Brain research 1993;622(1-2):79-85.
1993: Z Vogel; J Barg; R Levy; D Saya; E Heldman; R Mechoulam
Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase.
Journal of neurochemistry 1993;61(1):352-5.
1993: E Fride; R Mechoulam
Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent.
European journal of pharmacology 1993;231(2):313-4.
1993: T U Järbe; A J Hiltunen; D A Mathis; L Hanŭs; A Breuer; R Mechoulam
Discriminative stimulus effects and receptor binding of enantiomeric pairs of cannabinoids in rats and pigeons; a comparison.
The Journal of pharmacology and experimental therapeutics 1993;264(2):561-9.
1993: E Shohami; M Novikov; R Mechoulam
A nonpsychotropic cannabinoid, HU-211, has cerebroprotective effects after closed head injury in the rat.
Journal of neurotrauma 1993;10(2):109-19.
1992: W A Devane; L Hanus; A Breuer; R G Pertwee; L A Stevenson; G Griffin; D Gibson; A Mandelbaum; A Etinger; R Mechoulam
Isolation and structure of a brain constituent that binds to the cannabinoid receptor.
Science (New York, N.Y.) 1992;258(5090):1946-9.
1992: S H Burstein; C A Audette; A Breuer; W A Devane; S Colodner; S A Doyle; R Mechoulam
Synthetic nonpsychotropic cannabinoids with potent antiinflammatory, analgesic, and leukocyte antiadhesion activities.
Journal of medicinal chemistry 1992;35(17):3135-41.
1992: W A Devane; A Breuer; T Sheskin; T U Järbe; M S Eisen; R Mechoulam
A novel probe for the cannabinoid receptor.
Journal of medicinal chemistry 1992;35(11):2065-9.
1992: R G Pertwee; L A Stevenson; D B Elrick; R Mechoulam; A D Corbett
Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guinea-pig small intestine.
British journal of pharmacology 1992;105(4):980-4.
1991: D J Harvey; E Samara; R Mechoulam
Comparative metabolism of cannabidiol in dog, rat and man.
Pharmacology, biochemistry, and behavior 1991;40(3):523-32.
1991: R Mechoulam; W A Devane; A Breuer; J Zahalka
A random walk through a cannabis field.
Pharmacology, biochemistry, and behavior 1991;40(3):461-4.
1991: B R Martin; D R Compton; B F Thomas; W R Prescott; P J Little; R K Razdan; M R Johnson; L S Melvin; R Mechoulam; S J Ward
Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs.
Pharmacology, biochemistry, and behavior 1991;40(3):471-8.
1991: R Mechoulam; A Breuer; J J Feigenbaum; W A Devane
Nonpsychotropic synthetic cannabinoids as therapeutic agents.
Farmaco (Società chimica italiana : 1989) 1991;46(1 Suppl):267-76.
1990: R Mechoulam; A Breuer; T U Järbe; A J Hiltunen; R Glaser
Cannabimimetic activity of novel enantiomeric, benzofuran cannabinoids.
Journal of medicinal chemistry 1990;33(3):1037-43.
1989: J J Feigenbaum; F Bergmann; S A Richmond; R Mechoulam; V Nadler; Y Kloog; M Sokolovsky
Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker.
Proceedings of the National Academy of Sciences of the United States of America 1989;86(23):9584-7.
1989: J J Feigenbaum; S A Richmond; Y Weissman; R Mechoulam
Inhibition of cisplatin-induced emesis in the pigeon by a non-psychotropic synthetic cannabinoid.
European journal of pharmacology 1989;169(1):159-65.
1989: T U Järbe; A J Hiltunen; R Mechoulam
Stereospecificity of the discriminative stimulus functions of the dimethylheptyl homologs of 11-hydroxy-delta 8-tetrahydrocannabinol in rats and pigeons.
The Journal of pharmacology and experimental therapeutics 1989;250(3):1000-5.
1988: T U Jrbe; A J Hiltunen; R Mechoulam; M Srebnik; A Breuer
Separation of the discriminative stimulus effects of stereoisomers of delta 2- and delta 3-tetrahydrocannabinols in pigeons.
European journal of pharmacology 1988;156(3):361-6.
1988: R Mechoulam; J J Feigenbaum; N Lander; M Segal; T U Järbe; A J Hiltunen; P Consroe
Enantiomeric cannabinoids: stereospecificity of psychotropic activity.
Experientia 1988;44(9):762-4.
1988: E Samara; M Bialer; R Mechoulam
Pharmacokinetics of cannabidiol in dogs.
Drug metabolism and disposition: the biological fate of chemicals 1988;16(3):469-72.
1987: A R Martin; P Consroe; V V Kane; V Shah; V Singh; N Lander; R Mechoulam; M Srebnik
Structure-anticonvulsant activity relationships of cannabidiol analogs.
NIDA research monograph 1987;79():48-58.
1987: R Mechoulam; N Lander; M Srebnik; A Breuer; M Segal; J J Feigenbaum; T U Jarbe; P Consroe
Stereochemical requirements for cannabimimetic activity.
NIDA research monograph 1987;79():15-30.
1987: P Consroe; R Mechoulam
Anticonvulsant and neurotoxic effects of tetrahydrocannabinol stereoisomers.
NIDA research monograph 1987;79():59-66.
1987: L E Hollister; H K Gillespie; R Mechoulam; M Srebnik
Human pharmacology of 1S and 1R enantiomers of delta-3-tetrahydrocannabinol.
Psychopharmacology 1987;92(4):505-7.
1986: T U Järbe; A J Hiltunen; N Lander; R Mechoulam
Cannabimimetic activity (delta 1-THC cue) of cannabidiol monomethyl ether and two stereoisomeric hexahydrocannabinols in rats and pigeons.
Pharmacology, biochemistry, and behavior 1986;25(2):393-9.
1984: H Edery; G Porath; R Mechoulam; N Lander; M Srebnik; N Lewis
Activity of novel aminocannabinoids in baboons.
Journal of medicinal chemistry 1984;27(10):1370-3.
1983: E Gez; S Biran; Z Fuks; E Edelstein; N Lander; R Mechoulam
[A marihuana component for nausea and vomiting induced by chemo- and radiotherapy].
Harefuah 1983;105(10):306-8.
1982: P Consroe; M A Benedito; J R Leite; E A Carlini; R Mechoulam
Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice.
European journal of pharmacology 1982;83(3-4):293-8.
1982: J R Leite; E A Carlini; N Lander; R Mechoulam
Anticonvulsant effects of the (-) and (+)isomers of cannabidiol and their dimethylheptyl homologs.
Pharmacology 1982;24(3):141-6.
1980: R Mechoulam; N Lander; T H Varkony; I Kimmel; O Becker; Z Ben-Zvi; H Edery; G Porath
Stereochemical requirements for cannabinoid activity.
Journal of medicinal chemistry 1980;23(10):1068-72.
1980: A V Revuelta; D L Cheney; E Costa; N Lander; R Mechoulam
Reduction of hippocampal acetylcholine turnover in rats treated with (-)-delta 8-tetrahydrocannabinol and its 1',2'-dimethyl-heptyl homolog.
Brain research 1980;195(2):445-52.
1980: I Tamir; R Mechoulam; A Y Meyer
Cannabidiol and phenytoin: a structural comparison.
Journal of medicinal chemistry 1980;23(2):220-3.
1980: J M Cunha; E A Carlini; A E Pereira; O L Ramos; C Pimentel; R Gagliardi; W L Sanvito; N Lander; R Mechoulam
Chronic administration of cannabidiol to healthy volunteers and epileptic patients.
Pharmacology 1980;21(3):175-85.
1980: T Cordova; D Ayalon; N Lander; R Mechoulam; I Nir; M Puder; H R Lindner
The ovulation blocking effect of cannabinoids: structure-activity relationships.
Psychoneuroendocrinology 1980;5(1):53-62.
1970: R Mechoulam; A Shani; H Edery; Y Grunfeld
Chemical basis of hashish activity.
Science (New York, N.Y.) 1970;169(3945):611-2.